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Ursolic acid is a promising candidate for treatment of Chagas disease; however it has low aqueous 
solubility and intestinal absorption, which are both limiting factors for bioavailability. Among the 
strategies to enhance the solubility and dissolution of lipophilic drugs, solid dispersions are growing in 
popularity. In this study, we employed a mixture of the surfactants poloxamer 407 with sodium caprate 
to produce a solid dispersion containing ursolic acid aimed at enhancing both drug dissolution and in 
vivo trypanocidal activity. Compared to the physical mixture, the solid dispersion presented higher bulk 
density and smaller particle size. Fourier Transform Infrared Spectroscopy results showed hydrogen 
bonding intermolecular interactions between drug and poloxamer 407. X-ray diffractometry experiments 
revealed the conversion of the drug from its crystalline form to a more soluble amorphous structure. 
Consequently, the solubility of ursolic acid in the solid dispersion was increased and the drug dissolved 
in a fast and complete manner. Taken together with the oral absorption-enhancing property of sodium 
caprate, these results explained the increase of the in vivo trypanocidal activity of ursolic acid in solid 
dispersion, which also proved to be safe by cytotoxicity evaluation using the LLC-MK2 cell line.
Uniterms: Ursolic acid/trypanocidal activity. Chaga’s Disease/treatment. Solid dispersions/dissolution. 
Poloxamer 407. Sodium caprate.
O ácido ursólico é um candidato promissor para o tratamento da doença de Chagas, contudo este 
fármaco possui baixa solubilidade aquosa e limitada absorção intestinal, ambos os fatores limitantes 
da biodisponibilidade. Entre as estratégias para potencializar a solubilidade e a dissolução de fármacos 
lipofílicos, as dispersões sólidas estão crescendo em popularidade. Neste estudo, empregamos mistura 
dos tensoativos, poloxamer 407 e caprato de sódio, para produzir dispersão sólida contendo ácido 
ursólico, com o objetivo de aumentar tanto a dissolução do fármaco quanto a atividade tripanocida in 
vivo. Comparada à mistura física, a dispersão sólida apresentou maior densidade e menor tamanho de 
partícula. Os resultados da análise de espectroscopia no infravermelho com transformada de Fourier 
mostraram interações intermoleculares do tipo ligações de hidrogênio entre o fármaco e o poloxamer 407. 
Os experimentos de difratometria de raio-X revelaram a conversão do fármaco de sua forma cristalina 
para a forma amorfa, mais solúvel. Consequentemente, a solubilidade do ácido ursólico em dispersão 
sólida foi aumentada e o fármaco dissolveu-se de maneira mais rápida e completa. Em conjunto com as 
propriedades promotoras de absorção oral do caprato de sódio, estes resultados explicaram o aumento 
da atividade tripanocida in vivo do ácido ursólico em dispersão sólida, que também se provou segura 
após avaliação de citotoxicidade empregando a linhagem celular LLC-MK2.
Unitermos: Ácido ursólico/atividade tripanocida. Doença de Chagas/tratamento. Tensoativos. Dispersões 
sólidas/dissolução. Poloxamer 407. Caproato de sódio.
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INTRODUCTION
Chagas disease, a life-threatening pathology that 
affects approximately 15 million people, is caused by the 
parasite Trypanosoma cruzi (WHO, 2007). The etiological 
agent’s life cycle involves the mandatory passage through 
both vertebrate and invertebrate hosts, including man and 
the hematophagous triatomine bug, respectively (Coura, 
De Castro, 2002). Because of the bug’s abundance in 
low-income households, the parasite affects mainly the 
poor people living mostly in Latin America; thus Chagas 
disease has been broadly neglected by the government, 
pharmaceutical industry and the scientific community, 
which do not provide sufficient investment to control or 
eliminate the disease. The World Health Organization 
states that tropical neglected diseases, including Chagas 
disease, affect 1 billion people and traditionally rank low in 
international health agenda. However, it has been recently 
recognized that efforts to control and disappear neglected 
diseases can function as a route to socioeconomic 
development (Dobbish et al., 2012; WHO, 2010).
Since the end of the 1960s, only two drugs have 
been used for the treatment of Chagas disease: nifurtimox 
(Lampit₢) and benznidazole (LAFEPE₢). However, despite 
being effective in treating the acute phase of the infection, 
these drugs display limited efficacy in the chronic phase 
of the disease and are associated with several side-effects, 
including hypersensitivity, dermatitis with cutaneous 
eruptions, depression of bone marrow and polyneuropathy 
(Jannin, Villa, 2007; Coura, De Castro, 2002). Therefore, 
it is urgent to discover new drugs to treat Chagas disease 
that are highly efficacious in both the acute and chronic 
phases and are devoid of side-effects (Saraiva et al., 2011).
Ursolic acid (38-hydroxy-urs-12-en-28-oic acid), 
shown in Figure 1, is a naturally occurring pentacyclic 
triterpenoid compound that possesses important 
pharmacological properties including hepatoprotective 
(Saravanan, Viswanathan, Pugalendi, 2006), antioxidant 
(Ramachandran, Prasad, 2008), immunomodulatory 
(Raphael, Kuttan, 2003), antiglycative (Wang et al., 
2010), vasorelaxant (Aguirre-Crespo et al., 2006) 
and antimutagenic (Resende et al., 2006) functions. 
Furthermore, ursolic acid is a potential candidate for the 
treatment of Chagas disease due to its activity against 
Trypanosoma cruzi (Cunha et al., 2006; Ferreira et al., 
2010).
Despite ursolic acid’s high potential as a therapeutic 
option for Chagas disease, this drug has a very limited 
bioavailability due to its very low solubility in water (Liu, 
2005). To overcome this disadvantage, some alternatives 
have been proposed, including complexation with 
cyclodextrines (Li, 2009) and encapsulation in liposomes 
(Both et al., 2002); however none of these approaches have 
been evaluated for the enhancement of the trypanocidal 
activity. In previous studies, our group incorporated ursolic 
acid in solid dispersion formulations, which are mixtures 
of lipophilic drugs and hydrophilic carriers, resulting in 
improvement of drug solubility and dissolution profile as a 
consequence of decreased particle size, improved wettability 
and presence of drug in the more soluble molecular or 
amorphous state (Eloy et al., 2012a; Eloy, Marchetti, 2014; 
Vasconcelos, Sarmento, Costa, 2007). In those studies, 
we employed the lipid mixture Gelucire 50/13 and the 
polymer poloxamer 407 as carriers and investigated the 
physicochemical aspects of the solid dispersion formation 
and we established the best method for the formulation 
preparation. Despite the in vitro enhancement of the 
trypanocidal activity of ursolic acid in solid dispersions, 
unpublished in vivo trypanocidal activity results of the 
formulations were not satisfactory. Moreover, ursolic acid 
is a class IV drug in Bioavailability Classification System 
(BCS) and thus it is relevant to develop new formulations 
containing more potent surfactants and oral absorption 
enhancers to increase ursolic acid bioavailability and, 
consequently, its trypanocidal activity.
Herein, we propose a novel formulation to enhance 
the in vivo trypanocidal activity of ursolic acid in 
solid dispersion containing poloxamer 407, a nonionic 
polymeric carrier with high surfactant and stabilizing 
properties already employed in solid dispersions 
(Goddeeris, Van den Mooter, 2008), and sodium caprate, 
an ionic oral absorption enhancer fatty acid (Lo, Huang, 
2000), that has already been proven to enhance the 
bioavailability of oleanolic acid, ursolic acid isomer (Tong 
et al., 2011). To our knowledge, this is the first paper on 
the association of poloxamer 407 and sodium caprate in 
the manufacturing of solid dispersions and also this is the 
first report on the evaluation of the in vivo trypanocidal 
activity of pharmaceutical formulations containing ursolic 
acid. In the present work, we prepared the formulation and 
the physical mixture, characterized them by drug content, 
particle size, bulk density, Fourier infrared spectroscopy, 
X-ray diffractometry, solubility, drug dissolution profile 
and we evaluated the cytotoxicity against LLC-MK2 cells 
and the in vivo trypanocial activity.
MATERIAL AND METHODS
Compounds
Ursolic acid was purchased from IDEALFARMA. 
Sodium caprate was obtained from SIGMA. Poloxamer 
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407 was a kind gift from BASF. HPLC-grade acetonitrile 
and methanol were purchased from MERCK.
Physical mixture and solid dispersion preparation
Solid dispersion was prepared following a solvent 
evaporation method previously described by our group 
(Eloy et al., 2012a; Eloy, Marchetti, 2014). Briefly, 
the drug, poloxamer 407 and sodium caprate (0.2:1:1), 
w/w/w) were solubilized in methanol (10% w/v), followed 
by evaporation of the solvent at room temperature with 
magnetic stirring. Subsequently, the dispersion was 
stored in an oven at 40 °C for 24 h to allow the complete 
evaporation of methanol and then pulverized with a mortar 
and pestle. A physical mixture of the drug and carriers at 
the same ratio was prepared by simple mixing the drug 
and carriers and it was used as a formulation control for 
the experiments.
Particle size
The particle size of the physical mixture and solid 
dispersion was measured by a laser diffraction size 
analyzer using a Beckman Coulter LS 13 320.
Bulk density
A volumetric cylinder containing the powder was 
tapped (500) and the powder density was calculated 
based upon the weight of the sample and its volume as 
indicated by the volumetric cylinder before or after tapping 
(Goddeeris, Van Mooter, 2008).
Fourier infrared transform spectroscopy (FTIR)
FTIR experiments were performed using a 
Shimadzu IRPrestige-21 instrument. The samples were 
previously ground and mixed thoroughly with potassium 
bromide. The potassium bromide discs were prepared by 
compressing the powders in a hydraulic press. Scans were 
obtained at a resolution of 2 cm−1 from 4000 to 400 cm−1.
X-ray Diffractometry (XRD)
XRD measurements of the samples were collected 
on a Siemens/D5005 instrument with a copper anode 
operated at CuK radiation (1.5406 A, 40 kV and 30 mA). 
Patterns were obtained using a step width of 0.05°C/s over 
a range from 2° to 50° at room temperature on a 2θ scale.
Drug content
Determination of drug content in the samples 
was conducted using a high performance liquid 
chromatography (HPLC) method previously developed 
and validated at our laboratory (Eloy et al., 2012b). 
The method employed a Shimadzu HPLC system 
consisting of a LC-10ADVP pump, a SPD-10A VP UV 
detector (operating at 203 nm), a Rheodyne injector 
and a model CR6-A integrator. An acetonitrile:water 
(88:12, v/v) system was used as the mobile phase 
at a flow rate of 1.0 mL/min with a total injection 
volume of 20 µL. Separation was performed on a C18 
reverse-phase column (LiChrospher® (Merck), 250 x 
4 mm (5 µm)) at room temperature (25 °C). For the 
determination, triplicate samples were weighted, diluted 
with acetonitrile, filtered (0.45 µm) and analyzed.
Solubility determination
The solubility in water of free ursolic acid, in a 
physical mixture and in solid dispersion was determined 
by adding excess drug (10 mg) to 10 mL of distilled 
water under magnetic stirring (300 rpm) at 25 °C in a 
temperature controlled water bath until equilibrium was 
achieved (24 h). Triplicate samples were then filtered 
(0.45 µm), suitably diluted with acetonitrile and analyzed 
by HPLC.
In vitro drug dissolution
Dissolution studies were performed using an SR8 
Plus Hanson Corporation instrument (Chatsworth, CA, 
USA) by incubating a known amount of sample (equivalent 
to 7.5 mg drug) in 900 mL of pH 6.8 phosphate buffer 
(37 °C ± 0.2 °C) with mechanical stirring at 75 rpm with 
a paddle (Eloy et al., 2012a; Eloy, Marchetti, 2014). At 
designated time intervals, 1-mL aliquots were withdrawn 
and filtered (0.45 um), and then the drug was analyzed 
by HPLC, following the method already described. The 
withdrawn volume was replaced with the same amount 
of fresh dissolution medium. Dissolution was performed 
under sink conditions in triplicate. Statistical analyses 
FIGURE 1 - Chemical structure of ursolic acid.
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were carried out with the Prisma 5.0 Software (GraphPad, 
San Diego, California) using ANOVA with Dunnett’s 
multiple test. Differences were considered statistically 
significant when P<0.05.
Cytotoxicity
Samples were evaluated for cytotoxicity on LLC-
MK2 fibroblasts using the MTT method (Alves et al., 
2012). Briefly, LLC-MK2 cells (1x106 /mL) were cultured 
in 96-well plates containing the samples at the following 
dilutions: 8, 32, 128 and 256 µM. Plates were incubated 
in a CO2 incubator at 5% CO2 and 37 °C for 24 h. Ten µL 
MTT solution (5 mg/mL) was then added to each well, and 
plates were incubated for 4 h. Acid isopropyl (100 µL) was 
then added, followed by incubation at room temperature 
for 1 h. The plate was read on a spectrophotometer at 
595 nm. Statistical analyses were carried out with the 
Prisma 5.0 Software (GraphPad, San Diego, California) 
using ANOVA with Dunnett’s multiple test.
In vivo Trypanocidal activity
To evaluate the in vivo trypanocidal activity, male 
BALB/C albino mice (weighting, 20-22 g), were infected 
intraperitoneally with 2 × 104 T. cruzi trypomastigotes 
forms (Y strain), following a method employed by 
Ferreira et al. 2010. The treatment was initiated 48 h after 
infection and maintained for 14 days. The animals were 
randomly divided into four groups (n = 5), as follows: 
group I—untreated control (Negative control); group 
II—animals infected and treated with ursolic acid in 
physical mixture (UA PM); group III—animals treated 
with ursolic acid in solid dispersion prepared with sodium 
caprate and poloxamer 407 (SD CAP/POL); group IV—
animals treated with ursolic acid in solid dispersion 
prepared with poloxamer 407 (SD POL). Oral treatment 
was undertaken at the concentration of 20 mg/kg 
daily for 14 days, and the parasitemia was evaluated 
by counting the number of trypomastigote forms of the 
parasite per 5 µl of fresh blood, following the method 
described by Brener, 1962, with blood collected from 
the animal’s tail, starting at the second day of infection. 
The groups were subjected to their respective treatments 
in parallel. Statistical analyses were carried out with the 
Prisma 5.0 Software (GraphPad, San Diego, California) 
using ANOVA with Dunnett’s multiple test. Differences 
were considered statistically significant when P < 0.05. 
Experiments were approved by the committee on ethics 
of the College of Pharmaceutical Sciences of Ribeirão 
Preto (Protocol # 11.1.1029.53.6).
RESULTS AND DISCUSSION
Formulation preparation and characterization
Solid dispersions have been prepared previously by 
our group using the solvent evaporation and the fusion 
techniques and the former method was shown to be more 
suitable, producing particles with increased drug dissolution 
(Eloy, Marchetti, 2014). For this reason, in the present 
study we employed the solvent evaporation method for 
the production of solid dispersion with poloxamer 407 and 
sodium caprate and this procedure proved to be adequate 
for yielding a homogenous powder with no appreciable 
losses, as demonstrated by drug a content value equivalent 
to 101,82 ± 0,23 (%) of the drug amount added to the 
formulation; this result is comparable to those commonly 
observed for solid dispersions prepared using solvent 
evaporation methods, which have been extensively studied 
and are advantageous because they are inexpensive and 
industrially feasible (Vasconcelos, Sarmento, Costa, 2007; 
Frizon et al., 2013). The particle size of the solid dispersion 
powder compared the physical mixture was smaller, 
64.2 and 110.4 (µm), respectively, which may positively 
influence the drug solubility, due to increased surface area 
(Dhirendra et al., 2009). Moreover, the bulk density of 
the solid dispersion product revealed to be higher than the 
physical mixture, 0.67 compared to 0.31 g/cm3, respectively, 
which could represent and advantage for the incorporation 
of the solid dispersion powder in a tablet or a capsule 
because of the lower volume occupied.
Infrared spectroscopy is usually employed to 
determine the chemical structure of molecules by detecting 
the vibration of functional groups in the structure of 
the analyzed compound and is useful for detecting the 
occurrence of intermolecular interactions, which cause 
changes in the peak positions in the spectrum. FTIR spectra 
provided in Figure 2 show a reduced and broadened ursolic 
acid carbonyl peak at around 1700 cm-1, highlighted in 
the figure, for the solid dispersion compared to the sharp 
peak observed for the pure drug or physical mixture. This 
difference provides strong evidence of solid dispersion 
formation (Verheyen et al., 2002). These observations 
are explained by the fact that the carbonyl group, which is 
present in the ursolic acid structure (Figure 1), is capable of 
forming hydrogen bonding with hydroxyls of poloxamer 
407 when in a solid dispersion, causing the disappearance 
of or reduction in the intensity of the carbonyl group 
infrared peak, as has already been observed with solid 
dispersions formed between poloxamer 407 and ursolic 
acid (Eloy et al., 2012a; Eloy, Marchetti, 2014) and with 
ibuprofen (Ali, Willians, Rawlinson, 2010).
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X-ray diffractometry is  another important 
characterization technique in the study of solid dispersions, 
because it reveals the physicochemical state of the drug; 
crystalline structures are associated with defined peaks 
in the spectrum, whereas amorphous structures do not 
have diffraction peaks. XRD results, shown in Figure 
3, argue for the formation of solid dispersion, due to the 
reduced intensity of the ursolic acid crystalline peaks 
present at 6, 8 and 15°, evidenced in the figure, in the 
solid dispersion spectrum, compared to the pure drug and 
FIGURE 2 - FTIR spectra of ursolic acid (UA), poloxamer 407 
(POL), sodium caprate (CAP), physical mixture (PM) and solid 
dispersion (SD). Arrows indicate the carbonyl peak of ursolic 
acid.
FIGURE 3 - X-ray diffractometry of ursolic acid (UA), 
poloxamer 407 (POL), sodium caprate (CAP), physical mixture 
(PM) and solid dispersions (SD). Arrows indicate the diffraction 
peaks of ursolic acid.
physical mixture spectra, where the same peaks remained 
sharp. This finding confirmed the drug conversion from its 
usual crystalline form to the amorphous form, which was 
previously observed with etoricoxib by Chauhan, Shimpi 
and Paradkar (2005) and also with ursolic acid in our 
previou study with other carriers (Eloy, Marchetti, 2014).
Among the factors that influence the solubility of a 
drug in solid dispersion, the most relevant are hydrogen-
bonding intermolecular interactions, the physicochemical 
nature of the drug (i.e. whether the drug is crystalline 
or amorphous) and the particle size. The formation of 
hydrogen-bonding results in an intimate contact between 
the drug and carrier with consequent improvement of 
drug solubility influenced by the hydrophilic nature of 
the polymer, whereas the conversion from the organized 
crystalline to the disorganized amorphous form means a 
physicochemical more favorable solubilization process 
because there is no crystal lattice to be broken in the 
drug dissolution (Taylor, Sografi, 1997). Taken together 
with the reduced particle size, these factors explained 
the enhancement in the drug aqueous solubility from 
450.09 ± 15.98 to 978.98 ± 110.63 µg/mL for the physical 
mixture and solid dispersion, respectively, whereas pure 
ursolic acid solubility was less than 1 µg/mL. It should 
be emphasized that the solubility value achieved for the 
ursolic acid in solid dispersion described in this paper is 
12 times higher than that determined for another solid 
dispersion prepared with the lipid mixture Gelucire 
50/13 with the same drug load (Eloy et al., 2012a), and 
considerably superior to the solubility of the drug when 
prepared with poloxamer 407 alone, corresponding 
to 689.47 µg/mL (Eloy, Marchetti, 2014). The results 
demonstrate that poloxamer 407 and sodium caprate 
are a better surfactant carrier system for ursolic acid. 
Regarding the poloxamer 407 and sodium caprate ratio 
in the formulation, we prepared other solid dispersion 
formulations with more sodium caprate, however no 
further improvement of ursolic acid solubility could be 
found (data not shown).
In contrast to the physical mixture, the dissolution 
of ursolic acid from the solid dispersion shown in Figure 
4 was complete and fast, equivalent to 100% of the total 
amount of drug after 15 minutes; this rate hypothetically 
allows a prompt therapeutic response after administration, 
which is desirable for the oral treatment of Chagas disease. 
Because the drug is a weak acid (pKa 5.29) (Du, Chen, 
2009), its dissolution is favored in the pH 6.8 phosphate 
buffer medium, in which the more soluble ursolic acid’s 
ionic form is predominant. Therefore, it is expected 
that drug will be preferably dissolved in the intestinal 
lumen (pH 6.8). Better dissolution rate is of paramount 
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importance to enhance lipophilic drug bioavailability, 
making it possible to reduce the effective therapeutic dose 
of the drug, possibly decreasing side effects (Vasconcelos, 
Sarmento, Costa, 2007). Improved wettability of particles 
with decreased size and micellar solubilization caused 
by self-assembling in the dissolution medium of the 
amphiphiles, as discussed in the paper by Jones, Leroux 
(1999), are the most relevant factors that influence the 
faster dissolution. In this study, the micellar solubilization 
of the lipophilic drug is certainly caused by the presence of 
the surfactants poloxamer 407 and sodium caprate.
Cytotoxicity and in vivo Trypanocidal activity 
evaluation
The results in Figure 5 show that the physical mixture 
and solid dispersion are not cytotoxic to Rhesus monkey 
kidney epithelial cells (LLC-MK2) even at the highest 
concentration analyzed, 256 µM, suggesting the safety of 
the formulations for the mammalian cell model studied. 
This result is in agreement with other reports on the safety 
of ursolic acid, which has not been shown to cause acute 
toxicity as measured by LD50 assays and biochemical 
parameters (Ferreira et al., 2010). Moreover, our cytotoxicity 
results based on the MTT assay demonstrated the safety of 
the surfactant poloxamer 407 used in the formulations up 
to a concentration of 256 µM. Sodium caprate, naturally 
found in milk, is an FDA approved food additive and it is 
regarded as highly safe and has already been used in the 
formulation of solid dispersions (Maher, 2009; Tong et al., 
2011). In our evaluation, 100% cell viability was maintained 
up to 128 µM.
The therapeutic potential of solid dispersions 
containing ursolic acid as an option for the treatment 
of Chagas disease was demonstrated using an in vivo 
trypanocidal activity assay (Figure 06). In this assay, 
the physical mixture (UA PM) showed no difference 
compared to the negative control (p > 0.05), whereas 
the drug incorporated in solid dispersion composed of 
poloxamer 407 and sodium caprate (SD CAP/POL), 
administered daily at 20 mg/kg/day, was able to induce 
a statistically significant reduction of the parasitemia at 
the parasitemic peak (p<0.05), proving the efficacy of the 
solid dispersion system. This result is in accordance with 
previous studies by our group, in which we demonstrated 
that the oral treatment with ursolic acid at 20 mg/kg/day, 
solubilized in DMSO, tween and ethanol prior to 
administration, was able to promote a similar decrease in 
parasitemia (Ferreira et al., 2010). Alternatively, the solid 
dispersion prepared with poloxamer 407 (SD POL) did 
not result in reduction in parasitemia, demonstrating that 
the presence of a potent oral absorption enhancer, such 
FIGURE 4 - Dissolution of ursolic acid in physical mixture 
(UA PM) and in solid dispersion (SD) in a phosphate-buffered 
medium at 37 ºC and 75 rpm. *P<0.05.
FIGURE 5 - Cellular viability of LLC-MK2 fibroblasts after 
incubation (24h) with different concentrations of poloxamer 407 
(POL), ursolic acid in physical mixture (UA PM) and in solid 
dispersion (SD). *P<0.05.
FIGURE 6 - Parasitemic curve of mice infected with 2 × 104 
trypomastigotes forms of the Y strain of T. cruzi and treated by 
oral route with: ursolic acid (20 mg/kg/day) in physical mixture 
(UA PM), in solid dispersion prepared with poloxamer 407 (SD 
POL), in solid dispersion prepared with poloxamer 407 and 
sodium caprate (SD CAP/POL) or none (Negative control). 
*P<0.05.
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as sodium caprate, is important to enhance the in vivo 
trypanocidal activity of ursolic acid.
The use of a solid dispersion as a vehicle to deliver 
ursolic acid was responsible for the enhanced in vivo 
trypanocidal activity. This result can be attributed to the 
more soluble amorphous ursolic acid performing hydrogen 
bonding with poloxamer 407, to the enhanced drug release 
caused by the micellar solubilization of poloxamer 407 
and, very importantly, to the oral absorption enhancer 
property of sodium caprate. There is strong evidence 
that ursolic acid bioavailability is also limited by the oral 
absorption because its isomer, oleanolic acid, belongs to 
class IV in the BCS and its bioavailability was enhanced 
by the presence of sodium caprate in the solid dispersion 
containing polyvinylpyrrolidone as a stabilizer (Tong et 
al., 2011). Thus, the enhancement of drug solubility and 
the faster dissolution achieved with poloxamer 407 may 
be insufficient to increase the drug’s bioavailability and the 
trypanocidal activity of ursolic acid. Therefore, employing 
a potent oral absorption enhancer such as sodium caprate 
in the formulation, which causes a reversible, mild and 
transient perturbation of both transcellular and paracellular 
ways in the intestinal epithelium, as discussed by Maher 
and collaborators (Maher, 2009), is necessary step in the 
exploration of ursolic acid’s high potential to treat Chagas 
disease, as demonstrated in this paper. Future studies 
will be conducted at our laboratory to investigate the 
pharmacokinetics of ursolic acid after oral administration, 
not only with solid dispersions but also with other types 
of formulations.
CONCLUSION
This study was the first report on the incorporation 
of the lipophilic and antichagasic drug ursolic acid in 
solid dispersion prepared with the surfactants poloxamer 
407 and sodium caprate. We used infrared spectroscopy 
and x-ray diffractometry to demonstrate that solid 
dispersion formation occurred through hydrogen bonding 
between the drug and poloxamer 407 and that the drug 
was converted from the crystalline to the more soluble 
amorphous form. Therefore, solid dispersion, presenting 
smaller particle size and higher bulk density compared to 
the physical mixture, enabled the marked enhancement 
of the drug’s solubility and its ability to be dissolved in a 
complete and fast manner, unlike with a physical mixture. 
The formulation was shown to be safe using a cytotoxicity 
evaluation with LLC-MK2 mammalian cell line and 
enhanced the in vivo trypanocidal activity of ursolic acid, 
a consequence of both the potent surfactant poloxamer 407 
and the oral absorption enhancer sodium caprate.
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